MS-325 for magnetic resonance angiography submitted for approval in the U.S.

2004 JAN 12 - (NewsRx.com & NewsRx.net) -- Schering, AG, Germany, (SCH) announced that MS-325, its new contrast agent for magnetic resonance angiography (MRA), has been submitted for marketing approval in the United States by its development partner, EPIX Medical, Inc., (EPIX).

MS-325 is, according to the company, the first magnetic resonance blood pool contrast agent which has successfully completed clinical development for vascular imaging.

"MS-325 offers a real breakthrough in the field of vascular imaging. It is an innovative MRA contrast agent for the detection of structural abnormalities, such as stenosis and aneurysm, in patients with known or …